The approach
A method disciplined enough to survive the room it’s presented in.
“Assumptions Aside” isn’t a slogan — it’s the operating principle. We strip out the wishful framing and rebuild the case on what the evidence can actually defend.
A The five phases
Ground in the evidence base
We inventory what is actually supported across clinical, regulatory, HTA, and HEOR sources — and just as importantly, what isn’t. The approved evidence sets the agenda, not the marketing deck.
Separate the signals
Clinical strength and access readiness are different questions. We score and present them separately, so a strong trial result is never mistaken for a settled payer story.
Translate to decisions
Each finding becomes an implication you can act on — an endpoint choice, a comparator, a price point, a target segment — framed for the body that will judge it.
Mark the boundaries
Every recommendation comes with its guardrails: the claims the evidence will not carry, the cross-trial bridges that aren’t clean, the markets where precedent doesn’t transfer.
Hand off something defensible
You leave with a briefing structured the way decisions get made — readable by your team, and resilient when a reviewer pushes back.
B Standing guardrails
The lines we hold on every engagement.
Directional, not overstated
Planning indicators are labeled as such — never dressed up as formal HTA outputs.
Segment discipline
Value claims stay inside the population the evidence actually supports.
No clean bridge, no claim
Indirect comparisons inform; they don’t get treated as head-to-head proof.
Jurisdiction-specific
We don’t import one market’s conclusions into another without local evidence.
Put the method to work
Hand us your hardest assumption.
The intake takes about three minutes. We’ll come back with where the evidence is strong, where it isn’t, and what we’d do about it.
~3 minutes · No obligation